Valemetostat Tosilate: First Approval

Valemetostat tosilate (valemetostat; EZHARMIA(®)), a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2 (EZH1/2), is being developed by Daiichi Sankyo Company, Ltd for the treatment of various haematological malignancies and solid tumours, including typ...

Descripción completa

Detalles Bibliográficos
Autor principal: Keam, Susan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705507/
https://www.ncbi.nlm.nih.gov/pubmed/36380144
http://dx.doi.org/10.1007/s40265-022-01800-5
Descripción
Sumario:Valemetostat tosilate (valemetostat; EZHARMIA(®)), a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2 (EZH1/2), is being developed by Daiichi Sankyo Company, Ltd for the treatment of various haematological malignancies and solid tumours, including types of non-Hodgkin lymphomas (NHL). Valemetostat was approved in Japan in September 2022 for the treatment of patients with relapsed or refractory adult T-cell leukaemia/lymphoma (R/R ATL), a subtype of NHL. This article summarizes the milestones in the development of valemetostat leading to this first approval for R/R ATL.

Ejemplares similares